Life
Eli Lilly's Strategic Moves and CAR-T Developments in Recent Podcast
The latest episode of 'The Readout LOUD' podcast discusses Eli Lilly's strategic acquisitions, Allogene's advancements in CAR-T therapies, and Merck's acquisition of Terns.
Editorial Staff
1 min read
In the recent episode of 'The Readout LOUD' podcast, industry developments were highlighted, focusing on Eli Lilly's acquisition strategies.
The podcast also covered Allogene's progress with its off-the-shelf CAR-T therapies, which could impact treatment accessibility and operational frameworks within oncology.
Additionally, Merck's acquisition of Terns was discussed, emphasizing the implications for their pipeline and how it may influence market positioning.